2. Anti-infection
  3. RSV
  4. Palivizumab

Palivizumab  (Synonyms: MEDI 493)

Cat. No.: HY-P9944 Purity: 99.43%
COA

Molarity Calculator

Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice.

For research use only. We do not sell to patients.

CAS No. : 188039-54-5

Size Price Stock Quantity
1 mg USD 280 In-stock
5 mg USD 700 In-stock
10 mg USD 1100 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Palivizumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice[1].
Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species

Humanized
In Vitro

Palivizumab has RSV neutralizing activity and an EC50 value of 0.95850 nM with IgG1 protein[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Palivizumab Related Antibodies
In Vivo

Palivizumab (0.625-5 mg/kg (i.m.) or 0.312-10 mg/kg (i.v.); single dose) can prevent respiratory syncytial virus infection in cotton mice[1].
Palivizumab (0.05 mg/kg; single dose; intranasally administered)can prevent RSV infection in mice[2].
Palivizumab (15 mg/kg; single dose; s.c.) can inhibit RSV induced airway neurogenic inflammation in rats[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: The cotton rat model of RSV infection[1].
Dosage: 0.625-5 mg/kg (i.m.) or 0.312-10 mg/kg (i.v.)
Administration: Intramuscular injection (i.m.) or intravenous injection (i.v.); single dose
Result: Reduced virus replication and did not cause RSV infection or pathological increase in both initial and secondary attacks.
Animal Model: BALB/c mice[2].
Dosage: 0.05 mg/kg
Administration: Intranasally administered; single dose
Result: Reduced the RSV load.
Animal Model: Capsaicin-induced neurogenic inflammation in the airways of rats[3].
Dosage: 15 mg/kg
Administration: Subcutaneous injection (s.c.); single dose
Result: Reduced neurogenic extravasation and neurogenic inflammation.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Palivizumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Palivizumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Palivizumab188039-54-5MEDI 493MEDI493MEDI-493RSVRespiratory syncytial virusantibodyrespiratory tract infectionInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Palivizumab
Cat. No.:
HY-P9944
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.